Waypoint Bio a biotechnology company based in NYC that provides novel cell therapies for solid tumours, has raised $14.5M as Seed funding.

Hummingbird Ventures led the round, with participation from Recode Ventures, Fifty Years and pre-seed leader Fifty Years.

The company plans to use the money to enhance its CAR-T-cell therapies that are effective against the tumor microenvironment and later Treg therapies for autoimmune disease.

Waypoint Bio, a biotechnology firm co-founded by CEO Xinchen Wang & CSO David Phizicky is advancing novel cell therapies for solid tumours using its proprietary spatial-pooled-screening technology and lab-in the-loop approach. The company’s current focus is on developing novel solid tumor cell therapies to treat cancer. However, its technology can be used for other drug discovery applications such as Treg therapies.

The co-founders have been joined by a team consisting of 11 researchers, engineers and scientists, as well as a diverse and expert Scientific Advisory Board.

• Melina Claussnitzer PhD, Broad Institute of Harvard & MIT
• Robbie Majzner, MD, Dana-Farber Cancer Institute
• Yvonne Chen, PhD, UCLA
• Shantanu Singh PhD, Broad Institute
• Ron Lennox, D.Phil. MBA, Biotech entrepreneur, and investor

FinSMEs

28/06/2024